Rheumatology Advance Access published online on June 24, 2008
Rheumatology, doi:10.1093/rheumatology/ken231
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Clinical characteristics of cytomegalovirus infection in rheumatic diseases: multicentre survey in a large patient population
1Department of Allergy and Immunological Diseases, Tokyo Metropolitan Komagome Hospital, 2Rheumatology Center, Japanese Red Cross Medical Center, Tokyo, 3First Department of Internal Medicine, University of Occupational and Environmental Health, Fukuoka, 4Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, 5Department of Internal Medicine, School of Medicine, Keio University, Tokyo, 6Department of Internal Medicine, Division of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical School, Saitama, 7Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, 8Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa and 9Department of Clinical Pathology and Immunology, Kobe University School of Medicine, Kobe, Japan.
Correspondence to:
Y. Takizawa, Department of Allergy and Immunological Diseases, Tokyo Metropolitan Komagome Hospital, Bunkyo-ku, 3-18-22 Honkomagome, Tokyo 113-8677, Japan. E-mail: ytaki-tky{at}umin.ac.jp
 |
Abstract |
|---|
Objective. To survey and elucidate the clinical characteristics of CMV infection in rheumatic disease patients.
Methods. A detailed questionnaire survey on CMV infection was carried out against rheumatic disease patients hospitalized in member hospitals, and the obtained clinical and/or laboratory data were analysed.
Results. Out of 7377 patients, 151 were diagnosed as having CMV infection. The underlying diseases ranged broadly, but SLE, microscopic polyangiitis, and dermatomyositis were the most common. Four were diagnosed histopathologically, and the others via positive CMV antigenaemia. In addition to oral corticosteroid for all but one patient, 81 were treated with pulsed methylprednisolone (MPSL), 64 with cyclophosphamide (CYC) and 36 with other immunosuppressants. Forty-four had a fatal outcome, for which presence of clinical symptoms, other infectious complications, lymphopenia, an older age (>59.3 yrs) and the use of pulsed MPSL were significant risk factors (P < 0.05) by univariate analysis. Multivariate analysis retained the first three (P < 0.05). The CMV antigenaemia count was significantly higher for the symptomatic than asymptomatic [10.1 (0.0–2998.0) vs 4.0 (1.3–1144.4)/105 PMNs, respectively, P < 0.05; threshold count: 5.6/105 PMNs]. No treatment benefit by anti-viral agent was observed as for survival.
Conclusion. CMV infection was mostly diagnosed by antigenaemia, and occurred among patients under strong immunosuppressive therapy using pulsed MPSL and/or immunosuppressants. Lymphopenia, presence of symptoms and other infections are significant risk factors for a poor outcome and pulsed MPSL and an older age may predict it. Patients were prone to be symptomatic with anti-genaemia count over 5.6/105 PMNs.
KEY WORDS: Cytomegalovirus, Rheumatic diseases, Immunosuppressive therapy, Pulsed methylprednisolone, Cyclophosphamide, Cytomegalovirus antigenaemia count, Old age, Lymphopenia
Submitted 22 December 2007;
revised version accepted 23 May 2008.
CiteULike 
Connotea 
Del.icio.us What's this?